In order to mount an effective anti-tumor CD8+ T cell response in the setting of an immunogenic tumor, TILs must be both active effector cells and have sufficient diversity of T cell receptors to provide specificity for the heterogenous antigens displayed by tumors. The gene discussed is CD8A; the disease is neoplasm.